|
CN107921143A
|
|
Method for treating parenchymal cancer
|
|
US2017080100A1
|
|
Delivery of antibodies to the central nervous system
|
|
WO2016090495A1
|
|
TARGETED α-L-IDURONIDASE CONJUGATES AND USES THEREOF
|
|
US2017326233A1
|
|
Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
|
|
JP2016006089A
|
|
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
AU2014259519A1
|
|
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
US2016367691A1
|
|
Targeted enzyme compounds and uses thereof
|
|
WO2014194428A1
|
|
Targeted heparan sulfatase compounds
|
|
WO2014194427A1
|
|
Targeted iduronate-2-sulfatase fusion proteins
|
|
CN104955946A
|
|
Targeted iduronate-2-sulfatase compounds
|
|
MX2015005982A
|
|
Aprotinin-derived polypeptide-antibody conjugates.
|
|
US2016106856A1
|
|
Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
|
|
WO2014026283A1
|
|
Peptide-dendrimer conjugates and uses thereof
|
|
MX2014015551A
|
|
Targeted iduronidase compounds.
|
|
WO2013078562A2
|
|
Targeted iduronate-2-sulfatase compounds
|
|
EP2785838A2
|
|
Targeted lysosomal enzyme compounds
|
|
WO2013056096A1
|
|
Polypeptide-opioid conjugates and uses thereof
|
|
AU2012204135A1
|
|
Aprotinin polypeptides for transporting a compound across the blood-brain barrier
|
|
WO2012037687A1
|
|
Therapeutic polypeptides and uses thereof
|
|
MX2013000250A
|
|
Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof.
|
